Entity

Time filter

Source Type

Mountain View, CA, United States

Vivus is a small pharmaceutical company headquartered in Mountain View, California, working in obesity, sleep, and sexual health. Vivus is developing an erectile dysfunction drug, Avanafil, that has completed Phase 3 clinical trials. The drug has been approved for use by the FDA, and will be sold under the trademark name Stendra. Stendra is the first and only oral ED treatment approved to be taken approximately 15 minutes before sexual activity.A documentary movie "Orgasm Inc." was made at Vivus in 2009 to document the process of creating a treatment for Female sexual arousal disorder .Vivus also developed an obesity drug, Qnexa , a combination of phentermine and topiramate, two existing weight-loss drugs. On July 17, 2012, The U.S. Food and Drug Administration approved Qsymia , made by Vivus, as an addition to a reduced-calorie diet and exercise for chronic weight management. The drug was approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure , type 2 diabetes, or high cholesterol . Wikipedia.


This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.


The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.


The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.


A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.


The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.

Discover hidden collaborations